Press Releases

Press Releases

  1. BTG Completes Enrolment of Phase II Clinical Trial of BGC20-0582 for Head Lice Infestation

  2. BTG plc Appoints Dr John Brown as Chairman Designate

  3. BTG plc: Interim Results for the Six Months Ended 30 September 2007

  4. BTG Licensee Tolerx Forms Collaboration with GlaxoSmithKline to Develop and Commercialise TRX4

  5. BTG plc: Close Period Update

  6. BTG plc: Board Changes

  7. BTG plc: Campath® commences pivotal phase III trial in multiple sclerosis

  8. BTG plc: Campath® approved for first-line use in Adult Leukemia

  9. BTG plc: 2007 Annual General Meeting and Interim Management Statement

  10. BTG plc: Orphan Drug Status Granted for Anticancer Drug Plevitrexed

  11. Preliminary Results Statement

  12. BTG Signs Agreement with Novacea and KuDOS for AQ4N

  13. BTG Continues Physical Sciences Divestment Programme Granting Two Licenses to Technology Patents Worth Up to $46m

  14. BTG plc: Close Period Update

  15. BTG Licensee Cougar Biotechnology Presents Positive Data on Prostate Cancer Compound at ASCO Symposium

  16. BTG Acquires Novel Opioid Agonist for Post-Operative Pain Control from CLL Pharma

  17. New Chief Medical Officer for BTG

  18. BTG's Plevitrexed Shows Promising Efficacy and Tolerability in a Phase I/II study